Abstract
676PD - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have